IL-17 blocking antibodies have been successfully used in the clinical treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis, but are still in early clinical trials (226). The gene discussed is IL17A; the disease is autoimmune disease.